Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Terns Pharmaceuticals Inc TERN

Healthcare Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid... see more

Current News (NDAQ:TERN)

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire 5 days ago

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2026

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire January 2, 2026

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire December 11, 2025

Terns Announces Pricing of Upsized $650 Million Public Offering

GlobeNewswire December 9, 2025

Terns Announces Proposed Public Offering

GlobeNewswire December 9, 2025

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

GlobeNewswire December 8, 2025

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

GlobeNewswire November 14, 2025

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

GlobeNewswire November 10, 2025
View More News ››

Opinion & Analysis (NDAQ:TERN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TERN)

Buy buddy buy.

Otherwise FOMO for you fellas out there today anyway,so good luck to all of you
coolfooldumbguy - November 3, 2025

TERN Breaking 10$ on the News

TERN Breaking 10$ on the News
10QKing - September 9, 2024

Terns Pharmaceuticals: A Promising Pipeline Targeting Seriou

http://beyondspx.com/2024/08/02/terns-pharmaceuticals-a-promising-pipeline-targeting-serious-diseases/
MikeTester - August 3, 2024
View more Bullboard ››

Equity Metals Corp.

Equity Metals Corp.

Equity Metals Corporation engages in the acquisition, exploration, and development of mineral and diamond properties in ...
View More »

Podcasts